日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis

代谢功能障碍相关的脂肪肝疾病通过巨噬细胞迁移抑制因子-CD44轴加速胰腺癌的进展和转移。

Yu, Qian; Song, Hui; Shi, Xiao-Ya; Zhu, Liang; Liang, Yu; Gong, Rui-Ning; Dong, Xiao-Wu; Liu, Shang-Long; Wang, Hai-Zhen; Wang, Ying-Luo; Cui, Jiu-Fa; Yang, Xiao-Nan; Chen, Ying; Gao, Chao; Yang, Zhan; Zhu, Qing-Tian; Li, Chang; Zhang, Huan; Ying, Jie-Er; Zheng, Mei-Fang; Tian, Yan-Tao; Hu, Hai-Tao; Shao, Xin-Xin; Li, Yue; Mo, Ming-Guang; Lu, Yun; Ma, Zheng; Fu, Shun-Li; Niu, Qing-Hui; Liao, Yuan-Yu; Zhao, Chen-Yang; Liu, Xin; Saluja, Ashok K; Wang, Ji-Gang; Li, Xiao-Yu; Guo, Song-Yue; Wang, Wei-Hua; Wang, Song; Liu, Bin; Lu, Guo-Tao; Ren, He

Serpina3c protects against metabolic dysfunction-associated steatotic liver disease in offspring induced by prenatal prednisone exposure

Serpina3c 可保护后代免受产前泼尼松暴露引起的代谢功能障碍相关的脂肪肝疾病的影响

Dai, Yongguo; Lu, Zhengjie; Peng, Yu; Liu, Kexin; Lu, Xiaoqian; Sun, Xiaoxiang; Wang, Yuxi; Yan, Xuerong; Chen, Zijie; Zhang, Ziyi; Zhang, Ning; Ailikaiti, Aihemaitijiang; Chen, Yiming; Yue, Quanrui; Guo, Yu; Chen, Liaobin; Wang, Hui

HELZ2 Regulates Apob mRNA Stability to Modulate Fatty Liver Disease and Atherosclerosis.

HELZ2 调节 Apob mRNA 稳定性以调节脂肪肝疾病和动脉粥样硬化。

LDI, A Lipid Droplet Inhibitor, Disrupts Lipid Accumulation and Modulates Hepatic Lipid Profiles in Fatty Liver.

LDI(一种脂滴抑制剂)可破坏脂质积累并调节脂肪肝中的肝脏脂质谱。

Kim Seunghee, Kim Yeojin, Paudel Sanjita, Kang In Young, Kim Suyeon, Kim Jeesoo, Park Sunmi, Koo Seung-Hoi, Kim Hyun Sung, Jun Dae Won, Park Jinyoung, Lee Hyunbeom, Lee Joonseok

p21(+)TREM2(+) senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease

p21(+)TREM2(+)衰老巨噬细胞促进炎症衰老和代谢功能障碍相关的脂肪肝疾病。

Salladay-Perez, Ivan A; Avila, Itzetl; Estrada, Lizeth; Alexandru, Andreea C; Ponce, Cristian; Dhingra, Anika; Torres, Grasiela; Deng, Christina Y; Hegde, Ronak; Gensheimer, Julia; Kale, Abhijit; Heckenbach, Indra; Hui, Simon; Edillor, Chantle; Soto, Jose A; Napior, Alexander J; Little, Isaiah; Larsen, Mark; Rose, Jacob; Farahi, Lia; Lopez Gonzalez, Edwin D J; Krieger, Matthew R; Chowdhury, Kushan; Sharma, Mridul; Jiang, Yuming; Williams, Kevin; Scheibye-Knudsen, Morten; Koehler, Carla M; Meyer, Jesse G; Mack, Julia J; Brenner, Charles; Bensinger, Steven J; Lagger, Cyril; de Magalhães, João Pedro; Schilling, Birgit; Singh, Rajat; Verdin, Eric; Lusis, Aldons J; Covarrubias, Anthony J

Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study"

GLP-1RA 使用后早期癌症风险降低:信号还是偏倚?:致编辑的信,主题为“胰高血糖素样肽-1受体激动剂可降低2型糖尿病合并代谢功能障碍相关脂肪肝病成人患者的肝脏和非肝脏并发症:一项目标试验模拟研究”

Jean, Shio-Shin; Lai, Chih-Cheng

Correspondence to letter to the editor 1 on "Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study"

致编辑的信函 1,主题为“胰高血糖素样肽 1 受体激动剂可减少 2 型糖尿病和代谢功能障碍相关脂肪肝病成人患者的肝脏和非肝脏并发症:一项靶向试验模拟研究”

Mao, Xianhua; Nguyen, Mindie H

HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on "High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease"

慢性肝病患者常规实践中HCC预测指标:对“高SAFE评分可预测病毒性和非病毒性肝炎以及代谢功能障碍相关脂肪肝疾病中的肝细胞癌”一文的社论的回应

Su, Tung-Hung; Kao, Jia-Horng

Letter to the editor on "Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023"

致编辑的信,主题为“2017-2023年美国成年人脂肪肝和肝纤维化的当前负担”

Yang, Sisi; Ma, Zhenxuan

Correspondence to editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease"

致编辑的信函,主题为“通过非侵入性检查对代谢功能障碍相关脂肪肝患者进行风险分层”

Lee, Hye Won; Kim, Seung Up